scientific presentations
MGTA-145 Stem Cell Mobilization
MGTA-145, in Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties for Autologous and Allogeneic Transplant
EBMT 2021 Annual Meeting Presentation, March 2021
MGTA-145, in Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties for Autologous and Allogeneic Transplant (Oral Abstract, #35)
TCT Annual Meeting Presentation, February 2021
MGTA-145 / Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient in vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells (Oral Abstract, #16)
TCT Annual Meeting Presentation, February 2021
MGTA-145/Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient in vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells of CD46-Transgenic and Thalassemia Mice (Abstract #2602)
ASH Annual Meeting Poster, December 2020
MGTA-145, In Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant (Oral Abstract #184)
ASH Annual Meeting Presentation, December 2020
Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of MGTA-145 Alone or in Combination with Plerixafor (Abstract #A325)
EBMT Annual Meeting Poster, Aug/Sept 2020
MGTA-145, in Combination with Plerixafor, Rapidly Mobilizes Large Numbers of HSCs in Humans That Can Be Gene Edited with CRISPR/Cas9 and Mediate Superior Engraftment to Standard-of-Care (Abstract #123)
ASGCT Annual Meeting Presentation, May 2020
MGTA-145/Plerixafor-Mediated HSC Mobilization Allows for Efficient In Vivo HSC Transduction and Stable Gene Marking in Murine Peripheral Blood Cells (Abstract #810)
ASGCT Annual Meeting Poster, May 2020
Phase 1 Clinical Study of MGTA-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ HSCs without G-CSF (Abstract #73)
TCT Annual Meeting Presentation, February 2020
Rapid and Robust Mobilization of CD34 + HSCs without G-CSF Following Administration of MGTA-145 Alone or in Combination with Plerixafor (Abstract #1961)
MGTA-117 (previously CD117-ADC) Conditioning Program
A Novel Short Half-life Anti-Human CD117-Amanitin ADC Exhibits Dual HSCT Conditioning and Anti-Leukemia Activity and Extends Survival in Multiple Preclinical Models of AML
EBMT Annual Meeting Poster, March 2021
A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML) (Abstract #1044)
ASH Annual Meeting Poster, December 2020
A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates (Abstract #5)
TCT Annual Meeting Presentation, February 2020
A Non-Genotoxic Anti-CD117 Antibody Drug Conjugate (ADC) Designed for Patient Conditioning Prior to Stem Cell Transplant and HSC-Based Gene Therapy Has a Broad Therapeutic Window Across Species (Abstract #44)
TCT Annual Meeting Presentation, February 2020
A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates (Abstract #610)
CD117-ADC Conditioning Program
A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Pre-clinical Models of Acute Myeloid Leukemia (AML) (Oral Abstract, #53)
TCT Annual Meeting Presentation, February 2021
A Single Dose Of Short Half-Life CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy In Nonhuman Primates (Abstract #0076)
EBMT Annual Meeting Poster, Aug/Sept 2020
CD45-ADC Conditioning Program
Targeted CD45 Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model as a Single Agent (Poster #242)
TCT Annual Meeting Presentation, February 2021
Reversing clonal hematopoiesis and associated atherosclerotic disease by targeted antibody-drug-conjugate (ADC) conditioning and transplant (Abstract #1843)
ASH Annual Meeting Presentation, December 2020
Single Agent CD45-targeted Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model (Abstract #2330)
ASH Annual Meeting Presentation, December 2020
A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Ameliorate Disease in Preclinical Autoimmune Disease Models and Enable Auto HSCT (Abstract #0030)
EBMT Annual Meeting Poster, Aug/Sept 2020
A CD45-targeted Antibody Drug Conjugate Enables Allogeneic Hematopoietic Stem Cell Transplantation as a Single Agent in Mice (Abstract #A174)
EBMT Annual Meeting Poster, Aug/Sept 2020
A Novel Targeted Approach to Achieve Immune System Reset: A Single Dose of Magenta CD45-Targeted Antibody Drug Conjugate Enables Autologous HSCT and Ameliorates Disease in Murine Models of Autoimmune Disease (Abstract #3208)
ASH Annual Meeting Poster, December 2019
Administration of a CD45 Antibody Drug Conjugate As a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease (Abstract #120)
MGTA-456 Cell Therapy
MGTA-456, A CD34 Expanded Cord Blood Product, Permits Selection of Better HLA Matched Units and Results in Rapid Hematopoietic Recovery, Uniform Engraftment and Reduced Graft-
Versus-Host Disease in Adults with High-Risk Hematologic Malignancies (Oral Abstract, #31)
TCT Annual Meeting Presentation, February 2021
High Dose Stem Cell Therapies, Like MGTA-456, Enable
Complete Neural and Peripheral Disease Cross-Correction Through Rapid and Robust Hematopoietic Engraftment (Abstract #A325)
EBMT Annual Meeting Poster, Aug/Sept 2020
High Dose Hematopoietic Stem Cell Therapies, like MGTA-456, Enable Complete Neural, Peripheral, and Skeletal Disease Cross-Correction Through Rapid and Robust Engraftment (Abstract #248)
ASGCT Annual Meeting Poster, May 2020
MGTA-456 Cell Therapy in Inherited Metabolic Diseases (IMD) Yields Rapid and Durable LongTerm Improvement of Disease-Specific Outcomes in a Phase 2 Trial (Abstract #20)
TCT Annual Meeting Presentation, February 2020
High Dose Hematopoietic Stem Cell Transplantation Leads to Rapid Neural and Peripheral Disease Cross-Correction via Robust Hematopoietic and Microglia Recovery
TCT Annual Meeting Poster, February 2020
MGTA-456, An Aryl Hydrocarbon Receptor Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells, Permits Selection of Better HLA Matched Cord Units and Promotes Faster Neutrophil Recovery and Uniform Engraftment With Potentially Less Acute Graft-vs-Host-Disease (Abstract #804)
ASH Annual Meeting Presentation, December 2019
E478 Stem Cell Gene Therapy Expansion
Expansion with E478 Significantly Increases the Rate of CRISPR-Mediated Homology Directed Repair (HDR) and Improves Engraftment of Human Hematopoietic Stem Cells (Abstract #10)
ASGCT Annual Meeting Presentation, May 2020